The global antibody therapeutics market is poised for significant growth, projected to reach USD 479 billion by 2028 from USD 247.3 billion in 2023, exhibiting a robust CAGR of 14.1%. Key drivers fueling this growth include a surge in product approvals over the past five years and notable advancements in antibody engineering. Moreover, burgeoning opportunities in emerging economies further contribute to market expansion.

Segmented by format, disease area, route of administration, source, end-user, and region, the antibody therapeutics market showcases diverse dynamics. Among these segments, the human source holds the largest market share, with humanized sources witnessing notable growth, attributed to heightened demand for therapies, especially in cancer treatment, and their efficacy against cancers and autoimmune diseases.

In terms of administration, the intravenous route dominates the market, driven by its ease of use, high effectiveness, and the presence of numerous marketed products. Additionally, pipeline products largely focus on intravenous administration, further solidifying its dominance.

Overall, the antibody therapeutics market is positioned for robust growth, propelled by a combination of factors such as increased product approvals, advancements in antibody engineering, and expanding opportunities in emerging economies.

Know More